Evidence shows that inflammatory and immune processes within the brain might account for the pathophysiology of epilepsy. Therefore, developing new antiepileptic drugs that can modulate seizures through mechanisms other than traditional drugs is required for the treatment of refractory epilepsy. This study aims to determine the relationship between brain inflammation and epilepsy, to examine the contribution of some biochemical parameters involved in brain inflammation, and to address the effect of pharmacological interventions using some anti-inflammatory and immunomodulatory drugs in an experimental epilepsy model. Adult male rats were divided into seven groups of 20. G1 was the normal, non-treated control. G2 was the epileptic, non-treated group. G3-G7 were treated with celecoxib, methotrexate, azathioprine, dexamethasone, and valproate, respectively, for a period of three weeks. Induction of status epilepticus (SE) by Li-pilocarpine was performed on groups G2-G7. EEG tracing was conducted, and inflammatory mediators (brain and serum IL-1ß, IL 6, PGE 2 , HSP70, TGF-β2, and IFNγ) were measured. The induction of SE increased the amplitude and frequency of EEG tracing and inflammatory mediators more than in the normal control group. Treatments of epileptic rats reduced the frequency and amplitude of EEG tracing and significantly decreased the levels of inflammatory mediators in some treated rats compared to G2. These findings demonstrate that some anti-inflammatory and immunomodulatory drugs can lower the frequency and amplitude of seizures and reduce some inflammatory mediators in epilepsy treatments, strengthening the possibility that targeting these immunological and inflammatory pathways may represent another effective therapeutic approach to preventing epileptic seizures.
Introduction
Epilepsy is a neurological disorder identified by recurrent seizures that are often accompanied by cognitive deficits and mood disorders (Devinsky, 2004; Jones et al., 2008) . Because seizures are the result of uncontrollable neural excitation in the brain, epilepsy has primarily been considered a neurological disease. Most current antiepileptic drugs (AEDs) control neuronal excitability through a direct effect on ion channels. In fact, AEDs have at least two major setbacks. First, 20-30% of patients have poor seizure control that becomes medically intractable, even with optimal AED therapy. Second, AEDs generally depress the central nervous system (CNS) and impose marked inhibitory effects on cognitive development. Therefore, the development of new AEDs that can modulate seizures through another mechanism is required for refractory epilepsy treatment (Shimada and Takemiya, Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/brainres 2014).
In the last decade, clinical and experimental reports on the pathophysiology of epilepsy and seizures have extensively supported the hypothesis that the immune system and inflammatory processes inside the brain may encompass common and significant mechanisms (Riazi et al., 2010; Vezzani and Granata, 2005; Vezzani et al., 2011) . The primary understanding of the promising role of inflammation in epilepsy has resulted from clinical data demonstrating that steroids and other anti-inflammatory treatments have produced anticonvulsant activity in some epilepsies resistant to AEDs (Wheless et al., 2007) . Evidence was derived from febrile seizures (Dube et al., 2007) , which usually concur with, and are caused by, an increase in levels of proinflammatory agents (Dinarello, 2004) . Inflammation resulting from brain-damaging conditions, such as status epilepticus, trauma, stroke, infection, and hyperthermia, is accompanied by acute attacks of seizures and a high risk of developing epilepsy (Bartfai et al., 2007; Pitkanen and Sutula, 2002) . Data from some patients having seizure disorders with activated immune systems, an increased occurrence of seizures in autoimmune disorders, and the detection of limbic encephalitis as a reason for their epilepsy (Bien et al., 2007; Vincent and Bien, 2008) led to the hypothesis that inflammatory and immune mechanisms play critical roles in some types of epilepsy (Aarli, 2000; Devinsky, 2004) .
Preclinical and clinical studies have proven an intricate relationship between seizures and the immune method that is mediated via cytokines (Youn et al., 2013) . Numerous inflammatory intermediaries have been found in brain tissues surgically resected from patients with refractory epilepsies, such as temporal lobe epilepsy (TLE) and epilepsy related to cortical dysplasia (Devinsky, 2004; Shimada and Takemiya, 2014) . Some of these inflammatory mediators include IL1B, IL6, IFNγ (Uludag et al., 2015) , HSP70 (Turturici et al., 2011) , PGE 2 (Salvadori et al., 2012) , and TGF-β (Weissberg et al., 2015) .
Evidence that the immune system and inflammation are involved in the pathophysiology of epilepsy has raised the prospect of new therapeutic approaches for treating epilepsy and seizures that are resistant to currently available AEDs, and targeting inflammation-related pathways with anti-inflammatory and immunotherapies could have some advantages compared with using antiepileptic medications alone (Roberts and Goralski, 2008) .
The aims of this study were to determine the relationship between brain inflammation and epilepsy, to examine the contributions of some biochemical parameters involved in brain inflammation, and to address the effect of pharmacological interventions using some anti-inflammatory and immunomodulatory drugs in an experimental epilepsy model.
The experimental design is illustrated in Fig. 1 .
Results
Status epilepticus occurred in 100% of rats. The mortality rate ranged from 5% to 10% in different groups.
EEG tracing, Fig. 2(a-g)
The normal rat group (G1) (Fig. 2a ) featured a normal EEG record with background activity in the range of 11-12 Hz alpha waves that were mildly synchronous, well-organized, and of normal amplitude (from 20 to 80 mV). No focal sharp or spike wave activity was detectable.
The induction of SE in rats (Fig. 2b) produced EEGs of high amplitude (from 200 to 400 mV) with superimposed, mildly fast, and poly spike waves and slow background activity (6-7 Hz) in the theta range. This EEG trace denotes the development of EEG Recording Twenty-four hours after induction of SE by lithium-pilocarpine, the animals groups were subjected to EEG recording.
Group1

Control
Blood and Brain samples preparation
At the end of the experiment, rats were anesthetized with ether. Blood samples were withdrawn from the retroorbital venous plexus before scarification at 10 am. Rats were sacrificed and brains removed, forebrain dissected out and cerebellum discarded. epileptogenic clonic activity in the examined group.
In celecoxib-treated rats (Fig. 2c) , the induction of epilepsy resulted in EEGs that showed faster and lower amplitudes (100-160 mV) and background activity, when compared with the epileptic trace of the normal alpha range (11-12 Hz).
The EEG tracing in the methotrexate-treated epileptic group (G4) (Fig. 2d) showed the least improvement from the epileptic trace, with amplitude (80-180 mV) and a slow background theta activity (6-7 Hz).
The azathioprine-treated epileptic group (G5) (Fig. 2e) showed EEG tracings with a tendency toward amplitude improvement (60-170 mV) from the epileptic trace. This goes back to the normal alpha range frequency (9-10 Hz).
The injection of dexamethasone in the epileptic rats (G6) (Fig. 2f) showed an improvement in the EEG background activity more so than the epileptic trace in the form of wave amplitude (120-190 mV) , with a return to the normal alpha range frequency (10) (11) .
The injection of valproate in epileptic rats (G7) (Fig. 2g) showed EEG records with background activity in the alpha range (9-10 Hz) that were mildly synchronous and well-organized as well as wave amplitude of 100-180 mV. No focal sharp or spike wave activity was detectable.
Serum and brain inflammatory mediators (Tables 1 and 2)
In the present study, the induction of epilepsy by lithium/pilocarpine (Group 2) in rats significantly increased (p o0.001) brain IL-1B, IL-6, and HSP70 and brain and serum PG E 2 , compared to the normal control (Group 1).
In celecoxib-treated rats (Group 3), the induction of epilepsy produced significant decreases (p o0.001) in brain IL-6, serum and brain PG E 2 , and serum IFN-gamma, compared to epileptic nontreated rats (Group 2).
Treatment with methotrexate (Group 4) significantly decreased (po0.001) brain IL-6, HSP70, and TGF-B2 as well as serum PG E 2 and IFN-gamma, when compared to epileptic non-treated rats (Group 2).
In comparison with G2, azathioprine treatment (Group 5) significantly decreased (p o0.001) brain IL-6 and HSP70 and serum PG E 2 and IFN-gamma. . EEG Tracing in Different Groups. Fig. 2a There was a normal EEG record with background activity in the range of 11-12 Hz alpha waves that were mildly synchronous, well-organized, and of normal amplitude (from 20 to 80 mV). No focal sharp or spike waves activity was detectable. The induction of SE in rats ( Fig. 2b) produced EEGs of high amplitude (from 200 to 400 mV) with superimposed, mildly fast, and poly spike waves and slow background activity (6-7 Hz) in the theta range. This EEG trace denotes the development of epileptogenic clonic activity in the examined group. Fig. 2c EEGs showed a lower amplitude (100-160 mV) and faster background activity, when compared with the epileptic trace of the normal alpha range (11-12 Hz). Fig. 2d showed the least improvement from the epileptic trace with amplitude (80-180 mV) and a slow background theta activity (6-7 Hz). Fig. 2e showed EEG tracing with a tendency for an amplitude improvement (60-170 mV) from the epileptic trace. This goes back to the normal alpha range frequency (9-10 Hz). Fig. 2f showed an improvement in the EEG background activity more than the epileptic trace in the form of wave amplitude (120-190 mV) , with return to the normal alpha range frequency (10-11 Hz). Fig. 2g showed EEG records with background activity in the alpha range (9-10 Hz) that were mildly synchronous, well organized, and a wave amplitude (100-180 mV). No focal sharp or spike wave activity was detectable.
Dexamethasone (Group 6) significantly lowered (p o 0.001) brain IL-1B, IL-6, PG E2, and serum PG E 2, when compared with epileptic Group 2.
In valproate-treated rats (Group 7), when compared with the epileptic non-treated Group 2, the induction of epilepsy significantly reduced (p o 0.001) brain IL-6 and serum PG E2 and IFNgamma (Tables 1 and 2 ).
Discussion
In the present study, the induction of epilepsy by lithium/pilocarpine in rats produced an increase in the frequency and amplitude of the EEG tracing.
These results are in agreement with the findings of Morrisett et al. (1987) , who demonstrated that the administration of pilocarpine after lithium led to spike and seizure activities in 100% of treated rats. Pilocarpine injection induces EEG and behavioral limbic changes and status epilepticus, as recorded from the hippocampus and the cortex. Pilocarpine-induced SE causes massive neuronal damage when examined at 24-72 h. Pretreatment with LiCl seems to potentiate the effect of pilocarpine, since lithium, in combination with a lower dose of pilocarpine, induces the most consistent SE in rats. The onset and termination of SE are determined by behavioral seizures and EEG changes (Marchi et al., 2009; Reddy and Kuruba, 2013) . The lithium-pilocarpine rat model may prove valuable in the study of status epilepticus for a number of reasons. First, these seizures replicate generalized human epilepsy models. Second, the severity and refractory nature of this model indicates that lithium and pilocarpine are valuable for the development of new anticonvulsant agents. Finally, the delayed and consistent degree of status epilepticus is a useful tool for metabolic, neurochemical, and neuroanatomical studies of the extended seizure activity sequelae (Morrisett et al., 1987; Vezzani and Granata, 2005) .
Increased inflammatory mediators during epilepsy in the present study coincide with other studies. These studies suggested that brain pro-inflammatory conditions, developed after CNS problems such as SE, might play a role in epilepsy development (Gorter et al., 2006; Vezzani, 2014) . Studies on experimental models of induced seizures in rodents demonstrated a rapid onset of inflammatory response and the release of proinflammatory mediators that contribute to the mechanisms of ictogenesis from activated glia and neurons (Riazi et al., 2010; Vezzani and Granata, 2005; Vezzani et al., 2011) . Seizure activation results in neuronal cell loss and the destruction of the BBB (Ravizza et al., 2008) , and the breakdown of the BBB can increase neuronal excitability by enhancing inflammatory responses in the brain (Heinemann et al., 2012; Ransohoff et al., 2003) . Uludag et al. (2015) demonstrated that interleukin IL-1β, IL-6, and TNF-α inflammatory cytokine genes are up-regulated and activated in astrocytes and microglia after seizures. Also, IL-6 concentration increased chronically and was found to be more noticeable in CSF than in plasma, especially in TLE. Accordingly, the synthesis of IL-6 was thought to occur principally within the CNS (Billiau et al., 2007) , which coincides with the results of the present study. The increased prostaglandins after epilepsy induction in this study is confirmed by Takemiya et al. (2010) , who noted that epileptic seizures rapidly induce COX-2 in excitatory neurons and increase brain PGE 2 levels. COX-2-coupled PGE 2 production can promote seizures through mechanisms that drive epileptogenesis, such as the stimulation of inflammatory processes, a marked contribution in the reduction of seizure threshold with increases following seizures, and neuronal cell death (Salvadori et al., 2012) . Increased brain heat shock protein 70 (HSP 70) in this study coincides with studies that proved that HSPs can induce the innate immune system through their interactions with cell surface receptors, leading to the expression of proinflammatory cytokines, chemokines (Asea et al., 2000) , and the activation of dendritic cells (Floto et al., 2006) . HSPs are stress markers in temporal lobe epilepsy and are induced in response to some neurological diseases. There is a positive correlation between serum levels of HSP70 and the duration of epilepsy, hippocampal degeneration, and memory dysfunction, indicating that it can be used as a biomarker for stress-related neuronal damage (Chang et al., 2012) . Serum albumin extravasation into the cerebral cortex microenvironment due to BBB gaps stimulates the transforming growth factor beta (TGFβ) receptor-mediated signaling cascade in astrocytes (Cacheaux et al., 2009 ). The pleiotropic effects of the TGF-β signaling pathway produce a reasonable mechanism for epileptogenesis following brain injury and promote a specific therapeutic target (Weissberg et al., 2015) . Proinflammatory cytokine levels (IL-6 and IFN-γ) are elevated in the peripheral blood of patients with epilepsy (Mao et al., 2013) . IFN-γ plays an essential role in the development of the brain's excitatory seizure pathways, and it has been associated with the development of limbic seizures (Getts et al., 2007) .
Consequently, epileptic seizures and inflammatory mediators can reinforce each other, forming a positive feedback loop (Shimada and Takemiya, 2014) . These findings increase the probability that targeting these inflammatory pathways may serve as a useful therapeutic approach to preventing seizures (Morin-Brureau et al., 2011) .
In the present study, celecoxib (cyclooxygenase-2 inhibitor) showed a significant decrease in some brain and serum mediators and the frequency and amplitude of EEG tracing, compared to the epileptic non-treated group. These data are consistent with the findings of the study, which demonstrated that celecoxib reduced inflammatory mediators, decreased epileptic activities, and increased the seizure threshold (Schlichtiger et al., 2010) .
Treatments with methotrexate, azathioprine, and dexamethasone showed similar trends and decreased some brain and serum mediators and the EEG tracing. These results support the notion that anti-inflammatory and immunosuppressive therapies may be necessary in epilepsy and can produce better outcomes if combined with neuronal targeting.
ACTH and glucocorticoids have been used successfully in the treatment of some types of epilepsy (Suleiman et al., 2011) . Pilocarpine-induced seizures cause cerebrovascular changes (Leite et al., 2002) and induce seizures by an unpredicted immunologic activation mediated by specific receptors and adhesion molecules (Marchi et al., 2009) . Corticosteroids target these molecules, causing their depletion, which appears to protect against clinical or pilocarpine-induced seizures. Corticosteroids have an intense effect on human and rodent BBB permeability (Vezzani and Granata, 2005) ; therefore, corticosteroids oppose BBB leakage and seizures produced by the activation of the immune system.
Immunotherapy options for the treatment of epilepsy include different medications, and randomized controlled trials of immunotherapy in presumed autoimmune epilepsy are needed to provide further support for the rapid use of immunotherapy in patients with immune-mediated epilepsy (Melvin and Huntley Hardison, 2014; Ozkara and Vigevano, 2011) .
In the present study, valproate, used as an example of a traditional AED, produced a significant decrease in some serum and brain inflammatory mediators and frequency and amplitude of EEG recordings from the epileptic non-treated group. These results are supported by Himmerich and Bartsch's (2014) results. They demonstrated that valproic acid decreased the production of various cytokines, namely IL-1β, IL-2, IL-4, IL-6, IL-17, and TNF-α. Valproic acid has antioxidative and anti-inflammatory properties, which are consistent with decrease in mediators' production. It also has protective effects against various types of ischemia and reperfusion injury, as well as inflammatory diseases (Suda et al., 2013) .
In conclusion, these findings demonstrated that some anti-inflammatory and immunomodulatory drugs can lower the frequency and amplitude of seizures and reduce some inflammatory mediators during epilepsy treatment. This strengthens the possibility that targeting these immunological and inflammatory pathways may represent another effective therapeutic approach to preventing epileptic seizures.
Limitation of the study
All animals were pretreated, so it is hard to extrapolate to the clinical scenario where treatment would most likely be most effective afterward. This can be made use of in future experiments where the effect of tested drugs is monitored following the induction of SE.
Experimental procedure
Materials
Test drugs
Lithium Chloride (Powder), Dexamethasone (4 mg/ml), and Pilocarpine HCl (Sigma-Aldrich, MO, USA), Atropine Sulfate (1 mg/ 1 ml ampoule) (CDM Lavoisier, Paris, France). Methotrexate (5 mg/ 3 ml) (VHB Life Science Inc. India). Diazepam (Valium 5 mg/ml) (Roche, New Jersey, USA). Celecoxib (Celebrex 100 mg capsule) (Pfizer, New York, USA). Azathioprine (Imuran 50 mg tablet) (Aspen, Australia). Sodium Valproate (Depakine 200 mg tablets) (Sanofi Aventis, Paris, France), Ketamine HCl (100 mg/ml) (Woerden, Holland).
Chemicals and kits
All chemicals used in this study were of analytical grade. The kits used in this study are products of Sigma-Aldrich (Mybiosource Inc., San Diego, California, USA).
Experimental animals
One hundred and forty adult male Wistar rats weighing 275 725 g (King Fahd Research Centre, KAU, Jeddah) were used in the study. The rats were housed in standard polypropylene cages (five rats/cage) and maintained in a controlled environment at 2372°C and 45-55% humidity, with a 12/12-h modified darklight cycle (light from 7:00 a.m. to 7:00 p.m.). They were allowed a two-week accommodation before starting the experiment and were provided with water and food ad libitum. Procedures involving animals and their care were conducted in accordance with the approved guidelines of the UQU Animal Ethics Committee (HAPO-02-K-012-2015-05-116) . These guidelines comply with national and international laws and policies regulating animal research. Animals were examined twice daily for general body conditions, activity, seizures, feeding, and injury.
2. Methods
Induction of seizures by lithium-pilocarpine
Each rat received an intraperitoneal (ip) injection of LiCl (127 mg/kg). On the following day, each rat was injected with scopolamine methyl bromide (ip) (1 mg/kg) to alleviate the peripheral effects of pilocarpine. Approximately 30 min later, they were (ip) injected with pilocarpine hydrochloride (30 mg/kg) (Glien et al., 2001) . The consequential status epilepticus (SE) was characterized by continuous, secondary generalized clonic and clonic-tonic seizures starting 20-40 min following pilocarpine administration. Seizure behaviors were recorded for rearing or rearing with falling corresponding to stages 4-5 on the Racine scale (Racine, 1972) . Racine developed the scale by investigating the relationship between electroencephalogram (EEG) changes and the development of motor seizures. Only animals who developed stage 4-5 seizures were subjected to further investigation. One, four, and eight hours following seizure onset, the rats were (ip) injected with diazepam (15 mg/kg) to reduce their stress and distress and to increase their survival rate. In control animals, pilocarpine was substituted with saline (Zheng et al., 2010) .
Surgical details and EEG recordings
All surgeries were performed under anesthesia, and all efforts were exerted to minimize animal suffering. Surgical anesthesia was induced in rats by ketamine hydrochloride (80 mg/kg; SigmaAldrich, MO, USA) and xylazine hydrochloride (10 mg/kg ip; Sigma-Aldrich, MO, USA) (Kumar et al., 2013) . EEG recordings were performed using 8200-K2-SL: 2 EEG/1 EMG rat systems for seizures (Pinnacle, USA). Forehead skin was excised under general anesthesia to expose the skull and then cleaned and washed with Ringer solution. Two trephine openings (2 mm in diameter), frontal and occipital on each hemisphere, were made by drill bit into the skull to expose the cortical surface. Two 1/800 EEG screw electrodes with wire leads were gently screwed by a screwdriver in each hemisphere to avoid any wear and tear to the cortical surface. To avoid the drying of the cortical surface, Ringer solution was used frequently for washing at room temperature (Sallam, 2012) . Four electrodes were connected to the EEG headmount, which was connected to the six-pin swivel connecting to the amplifier via a cable to a computer running 9037 Sirenia s Seizure
Pro software. The EEG recordings in the experimental session were taken after a 10-15 min adaptation period and lasted for 10-15 min. The frequency spectra of 12 s successive EEG recordings in the range of 3-15 Hz were analyzed on the compatible computer.
4.2.3. EEG amplitude 4.2.3.1. Signals recorded from the skull surface. In each group, the amplitude (mV) and frequency (Hz) of the EEG responses were measured during the 10-15 min recordings. Settings for seizure detection were as follows: seizure duration, 4 2 s; minimum frequency, 3 Hz; the length of EEG kept before and after each seizure was 0.5 min (Abdullah and Rafiqul Islam, 2012; Lehmkuhle et al., 2009 ).
Blood and brain collection 4.3.1. Serum preparation
At the end of the experiment, rats were anesthetized with ether. Blood samples were drawn from the retroorbital venous plexus before being sacrificed at 10 a.m. Samples were collected in vacutainer tubes and centrifuged for 15 min at 1500 Â g under cooling. The resulting supernatant serum was immediately divided into 0.5 ml aliquots, transported at À 20°C, and stored at À 80°C until the biochemical analyses could be performed (Balosso et al., 2005) .
Brain preparation
Rats were sacrificed by decapitation, and their brains were removed 24 h (Arisi et al., 2015) after the induction of SE and after EEG recordings and blood samples were collected. Forebrains were dissected out and the cerebella were discarded. They were weighed and then homogenized immediately using a handheld homogenizer (CAT-SHM2; USA) in a known volume of ice-cold, phosphate-buffered saline (Sigma-Aldrich) (0.01 M phosphatebuffered saline; NaCl 0.138 M; KCl 0.0027 M/l pH 7.4) at 25°C. The homogenates were centrifuged for 15 min at 50,000 rpm and stored at À 80°C for inflammatory mediators' analyses the next day (Rabuffetti et al., 2000) .
Measurements of inflammatory mediators
Quantitative measurements of rat interleukin 1-ß (IL-1ß), interleukin 6 (IL 6), prostaglandin E 2 (PGE 2 ), heat shock protein 70 (HSP70), transforming growth factor β2 (TGF-β2), and interferon gamma (IFNγ) were carried out using commercially available enzyme-linked immunosorbent assay (ELISA) kits supplied by Sigma-Aldrich and Mybiosource Inc. (San Diego, California, USA) and according to the manufacturers' instructions. Each sample was assayed in duplicate, and the mean value was calculated.
Statistical methods
Data were analyzed using SPSS (Version 18.0). All values are expressed as mean 7SD. Analysis of variance (ANOVA), followed by multiple comparisons using Scheffe's test, were used. In all tests, Po 0.05 was considered statistically significant.
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